Liver disease stories

Jul 17, 2026

India approves Wegovy for fatty liver disease treatment

India's drug regulator approved Novo Nordisk's obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, expanding the drug's approved uses beyond weight loss.

Jul 17, 2026·1 source

Apr 17, 2026

First-in-Human Trial Shows Liver Transplant Patients Can Stop Immunosuppressants After Cell Therapy

UPMC and University of Pittsburgh researchers successfully weaned multiple liver transplant patients off all immunosuppressant drugs for over three years using a pre-transplant cell therapy approach, representing a potential breakthrough in organ transplantation.

Apr 17, 2026·2 sources

Top claims

▪The approved dosage of Wegovy for MASH treatment is a 2.4 mg semaglutide injection.
▪MASH is a serious form of fatty liver disease caused by a buildup of fat in the liver that can lead to inflammation and liver damage.
▪India's drug regulator, the Central Drugs Standard Control Organisation, approved Novo Nordisk's drug Wegovy for treating metabolic dysfunction-associated steatohepatitis (MASH).

Topics

Metabolic health Novo Nordisk Obesity treatment GLP-1 medications Clinical trials Regenerative medicine

Organ transplantation

Related entities

India Wegovy Immunosuppression

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources